Pharmaust Limited (ECQ0) AI Stock Analysis

Pharmaust Limited

(Frankfurt:ECQ0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved capitalizationThe sharp increase in equity provides a materially larger capital cushion than the prior year and may improve resilience while the company develops its business. Although losses remain significant, stronger capitalization can support operations and reduce immediate balance-sheet pressure.

Negative Factors

No recent revenueRevenue remaining at zero for three consecutive years indicates that the company has not yet established a recurring commercial base. Without sales generation, operating costs cannot be funded by customers, leaving future progress dependent on financing or successful commercialization.

Pharmaust Limited (ECQ0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 42.86M
Dividend Yield: ―
Average Volume (3M): 13.00K
Price to Earnings (P/E): -4.9
Beta (1Y): 0.41
Revenue Growth: ―
EPS Growth: 48.74%
Country: Germany
Employees: 36
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pharmaust Limited Business Overview & Revenue Model

Company Description

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is N...

Pharmaust Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:ECQ0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:PAR	47Neutral	AUD 153.48M	-1.61	-1189.87%	―	53.78%	-206.24%
AU:RCE	46Neutral	AUD 110.10M	-6.95	84.67%	―	―	42.51%
AU:PTX	44Neutral	AUD 60.62M	-7.68	-44.93%	―	―	25.27%
AU:BOT	41Neutral	AUD 27.63M	-0.31	-118.74%	―	499.47%	31.20%
AU:IMM	38Underperform	AUD 33.90M	-0.43	-98.86%	―	―	-27.73%

* Healthcare Sector Average

Performance Comparison

DE:ECQ0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:ECQ0	Pharmaust Limited	0.05	-0.01	-22.03%
AU:PAR	Paradigm Biopharmaceuticals Ltd.	0.24	-0.15	-37.97%
AU:IMM	Immutep Ltd	0.02	-0.26	-91.79%
AU:PTX	Prescient Therapeutics Limited	0.05	0.01	15.22%
AU:BOT	Botanix Pharmaceuticals Limited	0.01	-0.12	-92.31%
AU:RCE	Recce Pharmaceuticals Ltd.	0.36	-0.04	-10.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pharmaust Limited AI Stock Analysis